The abandonment of antibacterials: Why and wherefore?

Current Opinion in Pharmacology

Volumn 3, Issue 5, 2003, Pages 470-473

  Shlaes, David M ^a  

^a Idenix Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; PENICILLIN G; RIFAMPICIN; SULFONAMIDE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; ENTEROCOCCUS FAECIUM; FINANCIAL MANAGEMENT; HEALTH CARE COST; LAW; PHARMACY; POLITICS; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; MARKETING; RESEARCH; TECHNOLOGY, PHARMACEUTICAL;

EID: 0141646510     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.04.003     Document Type: Review

References (15)

1. Berkelman R.L. Hughes J.M. The conquest of infectious diseases: who are we kidding? Ann Intern Med 119 1993 426-427
2. National Nosocomial Infections Surveillance Report: Data summary from October 1986-April 1996. Am J Infect Control 1996, 24:380-388.
3. Shlaes D.M. Levy S. Archer G. Antimicrobial resistance: new directions Am Soc Microbiol News 57 1991 455-458
4. Lederberg J, Shope RE, Oaks SC Jr: Emerging Infections. Microbial threats to health in the United States. Washington DC: National Academy Press; 1992. [URL: http://www.iom.edu]
5. Murray B.E. Vancomycin-resistant enterococcal infections N Engl J Med 342 2000 710-721
6. DiMasi J.A. New drug development in the United States from 1963 to 1999 Clin Pharmacol Ther 69 2001 286-296
7. DiMasi J.A. Risks in new drug development: approval success rates for investigational drugs Clin Pharmacol Ther 69 2001 297-307
8. Kirst H.A. Thompson D.G. Nicas T.I. Historical yearly usage of vancomycin Antimicrob Agents Chemother 42 1998 1303-1304
9. Sievert D.M. Boulton M.L. Stoltman G. Johnson D. Stobierski M.G. Downes F.P. Somsel P.A. Rudrick J.T. Brown W. Hafeez W. et al. Staphylococcus aureus resistant to vancomycin - United States, 2002 Morbid Mortal Weekly Report 51 2002 565-567
10. Global WHO: Strategy for containment of antimicrobial resistance. Geneva: World Health Organization; 2001. [URL: http://www.who.int/csr/resources/publications/en/]
11. US Food and Drug Administration: Labeling requirements for systematic antibacterial drug products intended for human use. Code of Federal Regulations; 2003: 21 CFR Part 201 Docket No. 00N-1463. [URL: http://www.fda.gov]
12. US Food and Drug Administration: IDSA/PhRma/FDA Working Group Meeting; November 19-20 2002. [URL: http://www.fda.gov/cder/present/idsaphrma/default.htm]
13. US Food and Drug Administration: International Conference on Harmonization (ICH) of technical requirements for registration of pharmaceuticals for human use, guideline, choice of control group and related issues in clinical trials, May 2001. [URL: http://www.fda.gov/cder/guidance/4155fnl.htm]
14. Shlaes D.M. Moellering R.C. Jr. The United States Food and Drug Administration and the end of antibiotics Clin Infect Dis 34 2002 420-421
15. Interagency Task Force on Antimicrobial Resistance: A public health action plan to combat antimicrobial resistance. Part 1: domestic issues. [URL: http://www.cdc.gov/drugresistance/actionplan/aractionplan.pdf